GlassScriptPhysician profile
Brian L Joe
NPI 1740379304
$7,654.84
in general payments reported to CMS, 2019-2025
52 companies · $690 in 2025
The $690 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $969 · 2020: $829 · 2021: $1,553 · 2022: $1,312 · 2023: $1,427 · 2024: $875 · 2025: $690.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,785 · Consulting Fee: $150 · Education: $57.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,784.98 |
| Consulting Fee | $150.00 |
| Education | $57.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biogen, INC. | $858.58 | 2019-2025 | Tysabri, Vumerity, Plegridy |
| Novartis Pharmaceuticals Corporation | $841.64 | 2019-2025 | |
| Emd Serono, INC. | $681.60 | 2019-2025 | Mavenclad |
| Abbvie INC. | $611.24 | 2021-2025 | |
| Ucb, INC. | $548.83 | 2019-2025 | Briviact, Rystiggo |
| Amgen INC. | $375.77 | 2019-2022 | |
| Genzyme Corporation | $333.23 | 2019-2025 | |
| Teva Pharmaceuticals USA, INC. | $296.17 | 2019-2025 | Austedo Xr, Austedo Xr, Austedo |
| Sumitomo Pharma America, INC. | $256.77 | 2023-2024 | Aptiom |
| Lundbeck LLC | $247.98 | 2022-2025 | Vyepti |
| Alexion Pharmaceuticals, INC. | $245.39 | 2019-2025 | Ultomiris |
| Lilly USA, LLC | $199.48 | 2019-2025 | Kisunla, Emgality, Amyvid |
| Argenx US, INC. | $199.17 | 2022-2025 | Vyvgart Hytrulo, Vyvgart |
| Sk Life Science, INC. | $198.99 | 2020-2023 | |
| Genentech USA, INC. | $165.84 | 2019-2024 | Enspryng, Ocrevus, Ocrevus Zunovo |
Show all 52 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brian Joe listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.